Owen B. Wallace - Apr 12, 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Scientific Officer
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Apr 12, 2021
Transactions value $
$0
Form type
4
Date filed
6/25/2021, 05:00 PM
Next filing
Jun 23, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +387K $0.00 387K Apr 12, 2021 Common Stock 387K $6.14 Direct F1, F2, F3
transaction GLUE Stock Option (Right to Buy) Award $0 +113K $0.00 113K Jun 23, 2021 Common Stock 113K $19.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
F2 This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3 25% of this option shall vest and become exercisable on February 8, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.